Arrhythmias & electrophysiology
2-Hydroxybenzylamine for Treatment of Atrial Fibrillation: A First-in-Human Clinical Pilot Trial
Primary result · AF recurrence in the postablation population (smartwatch single-lead ECG)Result — go to the resultOdds ratio 3.65 95% CI 1.31–10.16Authors' conclusion
2-HOBA was associated with a higher risk of AF recurrence when tested early after AF ablation. This result was unexpected based on preclinical data, but paradoxical associations with AF have been previously reported for other drugs that target inflammation and oxidative stress pathways, such as omega-3 fatty acids. The mechanisms for AF immediately following ablation may be different from AF that occurs under other conditions, and the generalizability of these results to all forms of AF remains unknown.
Study context
- Population
- Patients with a planned atrial fibrillation (AF) ablation
- Comparison
- 2-HOBA vs placebo
Methodological detailsrandomized 1:1, placebo
- Randomized 1:1
- Placebo
Primary result
As reported in the abstract
Odds ratio
3.65
95% CI 1.31–10.16
P = 0.013
Further findings
Isolevuglandin levels · time of ablation
- No difference between the 2-HOBA and placebo groups
AF recurrence after study drug stopped · 12-month extended follow-up
- No difference between the 2-HOBA and placebo groups
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →